News

  1. Grand River Aseptic Manufacturing Announces $100 Million Investment In Sterile Manufacturing Capabilities 4/14/2026

    Grand River Aseptic Manufacturing (“GRAM”), an Arlington Capital Partners portfolio company, is a leading provider of sterile fill-finish services. The company has announced a significant investment to expand its sterile injectable drug product manufacturing capacity and capabilities for high-volume commercial products.

  2. Kindeva® Commemorates 70 Years Of The pMDI As Inventors Are Inducted Into The 'National Inventors Hall Of Fame' 3/26/2026
  3. CEO Insights And Trends: The Future Of The Sterile Filling CDMO Industry 3/17/2026

    Denis Johnson, CEO, explores developments in the CDMO sector and reveals how GRAM is gearing up for its latest phase of growth in sterile filling.

  4. BD Announces $110 Million To Support U.S. Pharmaceutical Supply Chain For Biologic Drugs 3/16/2026

    BD (Becton, Dickinson and Company) (NYSE: BDX), a leading global medical technology company, today announced a $110 million investment to expand its production of prefillable syringes, helping accelerate biologic and GLP-1 drug delivery and supporting pharmaceutical reshoring in the U.S.

  5. BD And Ypsomed Expand Partnership To Address Rapidly Growing Biologics Market 3/16/2026

    BD (Becton, Dickinson and Company) (NYSE: BDX), a leading global medical technology company, and Ypsomed, a leading developer of injection systems, are strengthening their collaboration with the development of a 5.5 mL version of the BD Neopak™ XtraFlow™ Glass Prefillable Syringe.

  6. Lifecore Biomedical Signs New Agreement With Indomo To Support Innovative Drug/Device Combination Acne Treatment 3/4/2026

    Lifecore Biomedical, Inc. (NASDAQ: LFCR) (“Lifecore”), a fully integrated injectables contract development and manufacturing organization (“CDMO”), and Indomo, a clinical-stage company dedicated to expanding access to quality healthcare via innovative device-enabled therapeutics, today announced that the companies have entered into a new development services agreement through which Lifecore will provide Indomo with a range of CDMO services to support the continued development of its corticosteroid drug candidate, DT-001.

  7. Subcutaneously Administered Nanotrastuzumab Matches Performance Of Herceptin HYLECTA In Minipig Study 2/12/2026

    Nanoform Finland Plc, the medicine performance-enhancing company, announced the results from a preclinical study designed to compare the tolerability and pharmacokinetics of Nanotratsuzumab, a nanoformed, novel, hyaluronidase-free, non-aqueous nanoparticle suspension of trastuzumab for subcutaneous delivery versus Herceptin HYLECTA™, a co-formulated product with Halozyme’s proprietary hyaluronidase enzyme marketed by Roche/Genentech.

  8. AbbVie To Buy Device Manufacturing Facility From West Pharmaceutical Services 1/14/2026

    The acquisition of the Tempe, Arizona facility will expand U.S.-based drug delivery device capacity and support the company’s $10 billion manufacturing investment.

  9. Halozyme Completes Acquisition Of Elektrofi, Expanding Breadth Of Offerings In Drug Delivery 11/20/2025

    Halozyme Therapeutics, Inc. (NASDAQ: HALO) ("Halozyme") today announced the successful completion of its acquisition of Elektrofi, Inc. ("Elektrofi"), a biopharmaceutical company with a proprietary ultra-high concentration microparticle formulation technology for biologics, branded Hypercon™

  10. Owen Mumford Launches EcoSafe® Safety Syringe Platform – Smarter For Budgets And Kinder To The Planet 10/29/2025

    Oxford - Medical device expert Owen Mumford has extended its 1ml safety syringe platform by adding a companion reusable autoinjector.